Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Buy" by Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given an average recommendation of "Buy" by the twenty ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $59.11.

Several analysts recently commented on the company. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim reaffirmed a "buy" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a research report on Monday, June 2nd. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 target price (up previously from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th.

Kymera Therapeutics Trading Down 0.4%

Shares of KYMR traded down $0.17 during trading hours on Thursday, hitting $46.18. The company had a trading volume of 501,454 shares, compared to its average volume of 618,113. The company has a market capitalization of $3.01 billion, a PE ratio of -14.90 and a beta of 2.18. Kymera Therapeutics has a one year low of $19.45 and a one year high of $53.27. The company's fifty day moving average price is $40.99 and its two-hundred day moving average price is $36.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm's quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.69) EPS. Analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of Kymera Therapeutics stock in a transaction on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the purchase, the director owned 6,117,295 shares in the company, valued at approximately $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 48,349 shares of company stock worth $2,334,301. Corporate insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC grew its stake in Kymera Therapeutics by 8.1% in the second quarter. Clear Harbor Asset Management LLC now owns 11,194 shares of the company's stock worth $489,000 after purchasing an additional 838 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Kymera Therapeutics by 8.4% in the second quarter. Harbor Capital Advisors Inc. now owns 33,472 shares of the company's stock worth $1,461,000 after purchasing an additional 2,594 shares in the last quarter. Rhumbline Advisers grew its stake in Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock worth $1,914,000 after purchasing an additional 5,771 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after purchasing an additional 491,737 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.